{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:09:16Z","timestamp":1771870156171,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T00:00:00Z","timestamp":1370908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00520-013-1857-9","type":"journal-article","created":{"date-parts":[[2013,6,9]],"date-time":"2013-06-09T23:10:32Z","timestamp":1370819432000},"page":"2879-2887","source":"Crossref","is-referenced-by-count":28,"title":["Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives"],"prefix":"10.1007","volume":"21","author":[{"given":"Selma","family":"Calcagnile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Lanzarotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus Peter","family":"Kammerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Timmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,11]]},"reference":[{"issue":"4","key":"1857_CR1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219\u2013227","journal-title":"Support Care Cancer"},{"issue":"1","key":"1857_CR2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdq600","volume":"22","author":"P Feyer","year":"2011","unstructured":"Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22(1):30\u201338","journal-title":"Ann Oncol"},{"issue":"5","key":"1857_CR3","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","volume":"21","author":"F Roila","year":"2010","unstructured":"Roila F, Herrstedt J, Aapro M, Gralla RJ et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(5):v232\u2013v243, www.mascc.org","journal-title":"Ann Oncol"},{"issue":"31","key":"1857_CR4","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2012","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC et al (2012) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncology 29(31):4189\u20134198, www.asco.org","journal-title":"J Clin Oncology"},{"key":"1857_CR5","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 1. (2012) www.nccn.org"},{"issue":"8","key":"1857_CR6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0959-8049(02)00674-3","volume":"39","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39(8):1074\u20131080","journal-title":"Eur J Cancer"},{"issue":"5","key":"1857_CR7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00130404-200609000-00003","volume":"12","author":"EB Rubenstein","year":"2006","unstructured":"Rubenstein EB, Slusher BS, Rojas C, Navari RM (2006) New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J 12(5):341\u2013347","journal-title":"Cancer J"},{"issue":"10","key":"1857_CR8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","volume":"14","author":"R Gralla","year":"2003","unstructured":"Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570\u20131577","journal-title":"Ann Oncol"},{"issue":"11","key":"1857_CR9","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","volume":"98","author":"Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99\u201304 Palonosetron Study Group","year":"2003","unstructured":"Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99\u201304 Palonosetron Study Group (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473\u20132482","journal-title":"Cancer"},{"issue":"2","key":"1857_CR10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115\u2013124, Epub 2009 Jan 8. Erratum in: Lancet Oncol. 2010 11(3):226","journal-title":"Lancet Oncol"},{"issue":"9","key":"1857_CR11","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","volume":"17","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441\u20131449","journal-title":"Ann Oncol"},{"issue":"2","key":"1857_CR12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1124\/jpet.110.166181","volume":"335","author":"C Rojas","year":"2010","unstructured":"Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, Slusher BS (2010) The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 335(2):362\u2013368, Epub 2010 Aug 19","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20133","key":"1857_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2012.01.046","volume":"684","author":"C Rojas","year":"2012","unstructured":"Rojas C, Slusher BS (2012) Pharmacological mechanism of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 684(1\u20133):1\u20137, Epub 2012 Mar 9","journal-title":"Eur J Pharmacol"},{"issue":"1\u20133","key":"1857_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2012.05.037","volume":"689","author":"M Stathis","year":"2012","unstructured":"Stathis M, Pietra C, Rojas C, Slusher BS (2012) Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol 689(1\u20133):25\u201330","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1857_CR15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.peptides.2012.06.010","volume":"37","author":"A Rizzi","year":"2010","unstructured":"Rizzi A, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, Pietra C, Calo' G (2010) In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist, Netupitant. Peptides 37(1):86\u201397","journal-title":"Peptides"},{"key":"1857_CR16","doi-asserted-by":"crossref","unstructured":"Giuliano C, Lovati E, Funk C, Potthast M, Pietra C, (2012) In vitro drug\u2013drug interaction studies with the antiemetic drug Netupitant and its major metabolites (M1 and M2), involving main human cytochrome P450 isoenzymes. Annals of Oncology 23 (Supplement 9): ix499\u2013ix527, doi: 10.1093\/annonc\/mds416 (abstract 1618)","DOI":"10.1093\/annonc\/mds416"},{"key":"1857_CR17","doi-asserted-by":"crossref","unstructured":"Lanzarotti C, Rossi G (2013) Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer (this issue), doi: 10.1007\/s00520-013-1855-y","DOI":"10.1007\/s00520-013-1855-y"},{"key":"1857_CR18","unstructured":"Palonosetron package insert (2012) Lugano, Switzerland. Helsinn Healthcare"},{"issue":"2","key":"1857_CR19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.6004\/jnccn.2012.0018","volume":"10","author":"JM Salsman","year":"2012","unstructured":"Salsman JM, Grunberg SM, Beaumont JL, Rogers M, Paul D, Clayman ML, Cella D (2012) Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw 10(2):149\u2013157","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"1857_CR20","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1093\/annonc\/mdq149","volume":"21","author":"MS Aapro","year":"2010","unstructured":"Aapro MS, Walko CM (2010) Aprepitant: drug\u2013drug interactions in perspective. Ann Oncol 21(12):2316\u20132323. doi: 10.1093\/annonc\/mdq149 , Epub 2010 May 20. Review","journal-title":"Ann Oncol"},{"key":"1857_CR21","unstructured":"EMEND (package insert) (2013) Merck Sharp & Dohme Corp., a subsidiary of Merck & CO., Inc., Whitehouse Station"},{"issue":"5","key":"1857_CR22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0149-2918(03)80128-5","volume":"25","author":"RA Blum","year":"2003","unstructured":"Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE (2003) Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 25(5):1407\u20131419","journal-title":"Clin Ther"},{"issue":"4","key":"1857_CR23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1185\/030079905X40481","volume":"21","author":"AK Shah","year":"2005","unstructured":"Shah AK, Hunt TL, Gallagher SC, Cullen MT Jr (2005) Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 21(4):595\u2013601","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"1857_CR24","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00520-008-0572-4","volume":"17","author":"LM Adams","year":"2009","unstructured":"Adams LM, Johnson B, Zhang K, Yue L, Kirby LC, Lebowitz P, Stoltz R (2009) Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Support Care Cancer 17(9):1187\u20131193","journal-title":"Support Care Cancer"},{"issue":"9","key":"1857_CR25","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00520-008-0571-5","volume":"17","author":"B Johnson","year":"2009","unstructured":"Johnson B, Adams L, Lu E, Zhang K, Lebowitz P, Lates C, Blum R (2009) Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer 17(9):1177\u20131185","journal-title":"Support Care Cancer"},{"issue":"11","key":"1857_CR26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1124\/dmd.104.000216","volume":"32","author":"RI Sanchez","year":"2004","unstructured":"Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE (2004) Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 32(11):1287\u20131292","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"1857_CR27","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270009353761","volume":"50","author":"BM Johnson","year":"2010","unstructured":"Johnson BM, Adams LM, Zhang K, Gainer SD, Kirby LC, Blum RA, Apseloff G, Morrison RA, Schutz RA, Lebowitz PF (2010) Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol 50(8):951\u2013959","journal-title":"J Clin Pharmacol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1857-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-013-1857-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1857-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:04:27Z","timestamp":1559081067000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-013-1857-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,11]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1857"],"URL":"https:\/\/doi.org\/10.1007\/s00520-013-1857-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,11]]}}}